Ingestible Therapeutic Platform
Treating Chronic Disease through the GI Tract
September 2023
This presentation (the "Presentation") is for informational purposes only and does not constitute or form any part of any offer or solicitation to buy or subscribe for securities of Epitomee Medical Ltd. (the "Company") and should not be regarded as a recommendation or an opinion on such matters. The information included in this Presentation is not comprehensive and does not include all the information with respect to the Company and its business required for any decision concerning an investment in the Company's securities. This Presentation includes forecasts, estimates, assessments, expectations and other information, intent or belief pertaining to future events and/or matters, which constitute "forward-looking statements" as defined in the Securities Law 5728-1968, which is based on current expectations, projections and assumptions about future events. Actual results may differ materially due to variety of factors, some of which the Company has no control over and cannot be reasonably foreseen at this date, including, but not limited to: dependency on third parties engaged by or who contracts the Company and its services, change in the overall economy; the duration and severity of the COVID-19 (coronavirus) pandemic and its impact on the Company and on local and global economy and the Company's ability to manage and develop its business. Such information may not materialize, in whole or in part, or may materialize in a manner significantly different to that forecast. Therefore, actual future results, performances or achievements of the Company may differ materially from what is or may be expressed or implied in this Presentation. Certain information and factual statements (including markets or trends) contained herein are based on or derived from publicly available documents or independent third-party sources the accuracy of such information and the assumptions on which such information is based have not been independently verified. The past performance information contained herein is not indicative of future results and there can be no assurance that the Company will achieve comparable results or that the Company will be able to implement its investment strategy or achieve any investment objective.
Shaping Your Health | 2
Management Team
Shimon Eckhouse, PhD | Dan Hashimshony, PhD |
Co-founder and Chairman | Chief Executive Officer |
Founder of Syneron Nasdaq:ELOS & Lumenis Nasdaq:LMNS, Sofwave Medical TLV: SOFW and others
Founder & CEO-Dune Medical Devices Chief Scientist X-technologies, and others
Gal Aharonowitz | Yael Kenen, PhD | Gil Cohen, PhD | Maya Gabrieli, CPA | Safi Landskroner | Dr. Ruthie Amir, MD. |
COO | VP Clinical Affairs | VP R&D | VP Finance | VP Business Development | Chief Medical & Regulatory Officer |
SHL, VP R&D Lumenis, | TEVA, Global Clinical Drug | SCO Dune Medical Devices, | Plastopil Hazorea LTD, | Dexcel Pharma, Mapi Pharma, | Global VP Regulatory |
GM Israel | Development Director | Hebrew University of Jerusalem | KPMG | Chartwell Pharmaceuticals | Syneron, Sofwave Medical |
Dune medical | |||||
Shaping Your Health | 3 |
Company Highlights
Breakthrough Tech | Market Potential | Strategic Alliances | |||
Ingestible, Shapeshifting Platform | Multi Billion $ Market | With Global Conglomerates | |||
• | Creates self-ingested, swallowable | • | Weight management >$200B | • | Weight management: |
devices that act along the GI tract | (Commercialization stage) | Global commercialization | |||
• | Achieves therapeutic outcomes in | • | Biologics delivery >300B | and marketing with Nestle | |
prevalent diseases | (Growth engine) | • | Biologics: Advancing collaborations | ||
with big pharma on biologic oral delivery |
Global Commercialization | Protected Innovation | Strong Cash Position |
Regulatory Progress | Intellectual Property | IPO TASE Dec 2021 |
• Cleared in: Europe, Israel | • 30 granted patents | • Current cash balance ~ $38M |
• Completed pivotal study for FDA 510(k) | • 12 pending patents | |
showing great clinical outcomes |
- Targeting FDA clearance & market launch in 2024
Shaping Your Health | 4
A Platform Technology with Various Applications
Adaptable in function, duration and location of operation
1 | Weight Management: |
active in the stomach |
ORAL ADMINISTRATION | TARGETED DEPLOYMENT |
Easy ingestion with no | Precise delivery to specific |
clinical procedures | therapeutic location |
TRANSIENT ACTIVITY | SAFE | |||
Temporary engagement | Designed with patient | |||
2 | Oral Biologics: drug carrier for | |||
and complete clearance | safety at the forefront | |||
delivery in the small intestine | ||||
Shaping Your Health | 5
Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Epitomee Medical Ltd. published this content on 12 September 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 September 2023 05:41:03 UTC.